-
Eupraxia Pharmaceuticals (EPRX) PT Lowered to $11 at H.C. Wainwright
-
Raymond James on Eupraxia Pharmaceuticals (EPRX): 'We See an Attractive Setup for 2026 Into Ph2b RESOLVE EoE Data'
-
Bloom Burton & Co. Starts Eupraxia Pharmaceuticals (EPRX) at Buy (1)
-
Raymond James Resumes Eupraxia Pharmaceuticals (EPRX) at Strong Buy
-
Eupraxia Pharmaceuticals (EPRX) PT Raised to $19 at Cantor Fitzgerald
-
Eupraxia reports positive tissue health data from EoE trial
-
Eupraxia's (EPRX) Blockbuster Opportunity Not Fully Priced In - Cantor Fitzgerald
-
Eupraxia reports 52-week data showing sustained symptom relief from EP-104GI
-
H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Eupraxia Pharmaceuticals (EPRX)
-
Eupraxia reports positive results from highest dose in EoE trial
-
Cantor Fitzgerald Reiterates Overweight Rating on Eupraxia Pharmaceuticals (EPRX)
-
Eupraxia reports sustained 12-month results from eosinophilic esophagitis trial
-
H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)
-
H.C. Wainwright Starts Eupraxia Pharmaceuticals (EPRX) at Buy
-
Canaccord Genuity Starts Eupraxia Pharmaceuticals (EPRX:CN) (EPRX) at Spec. Buy
-
Eupraxia Pharmaceuticals (EPRX) Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI
-
Craig-Hallum Starts Eupraxia Pharmaceuticals (EPRX) at Buy
-
Eupraxia Pharmaceuticals (EPRX) Announces CFO Succession
-
Rodman & Renshaw Starts Eupraxia Pharmaceuticals (EPRX) at Buy
-
Eupraxia Pharmaceuticals (EPRX) Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR
-
Eupraxia Pharmaceuticals (EPRX) Strengthens Senior Management Team
-
Eupraxia Pharmaceuticals (EPRX) Reports Data from RESOLVE Phase 1b/2a Trial of EP-104GI

